SG11202101757QA - Novel cancer immunotherapy antibody compositions - Google Patents
Novel cancer immunotherapy antibody compositionsInfo
- Publication number
- SG11202101757QA SG11202101757QA SG11202101757QA SG11202101757QA SG11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer immunotherapy
- antibody compositions
- novel cancer
- immunotherapy antibody
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720015P | 2018-08-20 | 2018-08-20 | |
| PCT/CN2019/101659 WO2020038379A1 (en) | 2018-08-20 | 2019-08-20 | Novel cancer immunotherapy antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101757QA true SG11202101757QA (en) | 2021-03-30 |
Family
ID=69591356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101757QA SG11202101757QA (en) | 2018-08-20 | 2019-08-20 | Novel cancer immunotherapy antibody compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12391758B2 (https=) |
| EP (1) | EP3841126A4 (https=) |
| JP (1) | JP7488534B2 (https=) |
| KR (1) | KR20210046725A (https=) |
| CN (3) | CN112839963B (https=) |
| AU (1) | AU2019324388A1 (https=) |
| BR (1) | BR112021003182A2 (https=) |
| CA (1) | CA3110138A1 (https=) |
| MX (1) | MX2021002077A (https=) |
| SG (1) | SG11202101757QA (https=) |
| TW (1) | TW202016150A (https=) |
| WO (1) | WO2020038379A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| JP2009504659A (ja) * | 2005-08-08 | 2009-02-05 | オンコノン・リミテッド・ライアビリティ・カンパニー | 抗体組成物、腫瘍性疾患の処置方法、および受胎能の調節方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) * | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| AR104484A1 (es) * | 2015-03-10 | 2017-07-26 | Sorrento Therapeutics Inc | Anticuerpos anti-psma como agentes terapéuticos |
| CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| CN106432501B (zh) | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017132562A1 (en) * | 2016-01-29 | 2017-08-03 | Heyue Zhou | Antigen binding proteins that bind pd-l1 |
| UA126905C2 (uk) | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Антитіло до pd-l1 та його застосування |
| CN106496327B (zh) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体 |
| CN108239149B (zh) * | 2016-12-25 | 2021-03-05 | 南京传奇生物科技有限公司 | 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体 |
| CN107973854B (zh) * | 2017-12-11 | 2021-05-04 | 苏州银河生物医药有限公司 | Pdl1单克隆抗体及其应用 |
| TWI840433B (zh) * | 2018-10-29 | 2024-05-01 | 大陸商北京強新生物科技有限公司 | 新穎合理設計的蛋白質組合物 |
-
2019
- 2019-08-20 MX MX2021002077A patent/MX2021002077A/es unknown
- 2019-08-20 CA CA3110138A patent/CA3110138A1/en active Pending
- 2019-08-20 SG SG11202101757QA patent/SG11202101757QA/en unknown
- 2019-08-20 TW TW108129705A patent/TW202016150A/zh unknown
- 2019-08-20 KR KR1020217008130A patent/KR20210046725A/ko not_active Abandoned
- 2019-08-20 EP EP19853152.7A patent/EP3841126A4/en active Pending
- 2019-08-20 BR BR112021003182-0A patent/BR112021003182A2/pt not_active IP Right Cessation
- 2019-08-20 CN CN201980054723.0A patent/CN112839963B/zh active Active
- 2019-08-20 AU AU2019324388A patent/AU2019324388A1/en not_active Abandoned
- 2019-08-20 CN CN202310026623.5A patent/CN116410320A/zh active Pending
- 2019-08-20 CN CN202211332831.XA patent/CN116063519B/zh active Active
- 2019-08-20 US US17/270,034 patent/US12391758B2/en active Active
- 2019-08-20 JP JP2021509199A patent/JP7488534B2/ja active Active
- 2019-08-20 WO PCT/CN2019/101659 patent/WO2020038379A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020038379A1 (en) | 2020-02-27 |
| CA3110138A1 (en) | 2020-02-27 |
| US12391758B2 (en) | 2025-08-19 |
| BR112021003182A2 (pt) | 2021-05-11 |
| CN116063519A (zh) | 2023-05-05 |
| CN112839963B (zh) | 2023-02-10 |
| TW202016150A (zh) | 2020-05-01 |
| JP2021534750A (ja) | 2021-12-16 |
| US20210332138A1 (en) | 2021-10-28 |
| AU2019324388A1 (en) | 2021-03-18 |
| EP3841126A4 (en) | 2022-08-10 |
| CN112839963A (zh) | 2021-05-25 |
| EP3841126A1 (en) | 2021-06-30 |
| KR20210046725A (ko) | 2021-04-28 |
| JP7488534B2 (ja) | 2024-05-22 |
| CN116063519B (zh) | 2026-04-28 |
| CN116410320A (zh) | 2023-07-11 |
| MX2021002077A (es) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288754A (en) | Preparations and methods for cancer immunotherapy | |
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| SG11202103317XA (en) | Combinatorial cancer immunotherapy | |
| IL280780A (en) | Anti-TIGIT antibodies | |
| SG11202103571XA (en) | Compositions and methods for immunotherapy | |
| SG11202108141VA (en) | Novel cd40-binding antibodies | |
| IL280013A (en) | Anti-IL36R antibodies | |
| EP4045054A4 (en) | Nano-enabled immunotherapy in cancer | |
| IL279352A (en) | IL-11RA antibodies | |
| IL292727A (en) | Multispecific antibodies | |
| IL278010A (en) | Antibodies to galectin 10 | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| IL277030A (en) | Antibodies | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| EP3892333A4 (en) | ANTI-TUMOR POLYIMMUNOTHERAPY | |
| SG11202100419UA (en) | Fcrn antibody compositions | |
| SG11202106053SA (en) | Compositions and methods for immunotherapy | |
| EP4025204A4 (en) | Cancer immunotherapy | |
| SG11202102114UA (en) | Anti-klrg1 antibodies | |
| IL289006A (en) | Combined immunotherapy for cancer | |
| IL286792B1 (en) | Cancer immunotherapy compositions and methods | |
| EP3858994A4 (en) | ANTIBODY COMPOSITION | |
| SG11202101757QA (en) | Novel cancer immunotherapy antibody compositions | |
| GB201903229D0 (en) | Immunotherapy | |
| GB201806084D0 (en) | Antibodies |